Global Opioid Induced Constipation Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025

  • ID: 4394886
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Astrazenenca
  • Daiichi Sankyo Co. Ltd.
  • Pfizer
  • Salix Pharmaceuticals Ltd
  • Shionogo & Co Ltd
  • Sucampo Pharmaceuticals
  • MORE

The opioid induced constipation drugs market was valued at USD 2111.05 Mn in 2017, and is expected to reach USD 2887.91 Mn by 2025, expanding at a CAGR of 4.6% from 2017 - 2025.

Market Insights

Alarming growth in opioid prescription for non-cancer pain has been a phenomenal event in the previous decade. As per the recent estimates, more than 40% of opioid consumers experience constipation and GI symptoms as side effects of opioid drugs. Rising pool of opioid users will lead to the growth in opioid induced constipation (OIC) prevalence thus contributing to OIC drugs market growth. The global opioid induced constipation drugs market was valued at USD 2111.05 Mn in 2017, and is expected to reach USD 2887.91 Mn by 2025, expanding at a CAGR of 4.6% from 2017 - 2025.

Methylnaltrexone bromide, lubiprostone and naloxegol are the three drugs currently indicated for OIC treatment. Among these, methylnaltrexone bromide holds the largest market size and is expected to progress with a CAGR of 2.9% during the forecast period. Relistor from Salix Pharmaceuticals is indicated for treatment of OIC in patients with advanced illness receiving palliative care, particularly when standard laxative therapy proves insufficient. Lubiprostone under the brandname Amitiza is indicated for treating OIC, where it major indication is for chronic idiopathic constipation (CIC). Lubiprostone is expected that the segment will take over the market share of methylnaltrexone bromide. Additionally, naloxegol is expected to grow at highest CAGR over the forecast period. The drug is under testing for various patient types such as pregnant women and patients less than 17 years of age. Thus, future approvals are expected to lead the market.

North America is the dominant regional OIC drugs market through the forecast period. Early bird approval of OIC drugs by the USFDA and high consumption of opioids in the US are the prime growth factors for the OIC drugs market in North America. On the other hand, Germany, UK, and Spain are the major countries setting the market dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of OIC drugs.

On the basis of prescription type the market is segmented into prescribed drugs and over the counter or OTC drugs. Constipation is never considered as a disease but a syndrome or a side effect; people are less likely to visit doctors to get prescription for constipation. Thus, the OIC drugs market is dominated by over the counter prescription with 65.87% market share in 2014. The OTC drug market will continue to dominate the market growing at the highest CAGR of 4.9% during 2017-2025.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astrazenenca
  • Daiichi Sankyo Co. Ltd.
  • Pfizer
  • Salix Pharmaceuticals Ltd
  • Shionogo & Co Ltd
  • Sucampo Pharmaceuticals
  • MORE
Chapter 1 Preface
1.1 Report Scope and Description
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Opioid Induced Constipation (OIC) Drugs Market Industry Snapshot

Chapter 3 Global OIC Drugs Market Analysis
3.1 OIC Drugs Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Increasing Use of Opioid
3.3.1.2 Elderly Population
3.3.1.3 Rising Opioids Prescription in North America and Europe
3.3.1.4 Large Range of Effective OIC Drugs Available
3.3.2 Restraints
3.3.2.1 Research on Pain and Next Generation Analgesics
3.3.2.2 Adverse Effects of OIC Drugs
3.3.2.3 Unawareness and hesitation among patients
3.3.2.4 Large number of considerations while using opioids
3.3.3 Opportunities
3.3.3.1 Emerging APAC Market
3.3.3.2 Rising Use of Opioids
3.4 Attractive Investment Proposition, 2017
3.5 Market Positioning of Key OIC Drugs Manufacturers

Chapter 4 Global OIC Drugs Market, by Drug Type
4.1 Overview
4.2 Methylnaltrexone Bromide
4.3 Lubiprostone
4.4 Naloxegol
4.5 Pipeline Drug Analysis: Phase 3: Naldemedine (Year of Launch to 2027 (USD Mn)
4.6 Pipeline Drug Analysis: Phase 3: Elobixibat (Year of Launch to 2027 (USD Mn)
4.7 Pipeline Drug Analysis: Phase 2: Alvimopan, Dolcanatide (Qualitative Information)

Chapter 5 Global OIC Drugs Market, by Prescription Type
5.1 Overview
5.2 Prescribed Drugs
5.2.1 Prescribed OIC Drugs Market, by Prescription Type 2017-2025 (USD Mn)
5.2.2 Prescribed OIC Drugs Market, by Prescription Type, 2017-2025 (USD Mn)
5.2.2.1 Prescribed Branded OIC Drugs Market 2017-2025 (USD Mn)
5.2.3 Over the Counter Drugs

Chapter 6 Global OIC Drugs Market, by Geography
6.1 North America
6.1.1 U.S.
6.1.2 Canada
6.2 Europe
6.2.1 U.K.
6.2.2 Germany
6.2.3 Rest of the Europe
6.3 Asia Pacific
6.3.1 China
6.3.2 Japan
6.3.3 Rest of Asia Pacific (APAC)
6.4 Rest of the World (ROW)
6.4.1 Middle East and Africa
6.4.2 Latin America
6.4.3 Rest of the ROW

Chapter 7 Company Profiles
7.1 Astrazenenca
7.1.1 Overview
7.1.2 Astrazeneca Product Portfolio
7.1.3 SCOT Analysis
7.2 Shionogo & Co Ltd
7.2.1 Overview
7.2.2 Shionogi product portfolio
7.2.3 Scot Analysis
7.3 Salix Pharmaceuticals Ltd
7.3.1 Overview
7.3.2 Salix Pharmaceuticals product portfolio
7.3.3 SCOT Analysis
7.4 Synergy Pharmaceuticals Inc
7.4.1 Overview
7.4.2 Synergy Pharmaceuticals Product Portfolio
7.4.3 SCOT Analysis
7.5 Cubist Pharmaceuticals (Adolor Corporation) - A Subsidary Of Merck
7.5.1 Overview
7.5.2 Cubist Pharmaceuticals Product Portfolio
7.5.3 SCOT Analysis
7.6 Sucampo Pharmaceuticals
7.6.1 Overview
7.6.2 Sucampo Pharmaceuticals Product Portfolio
7.6.3 SCOT Analysis
7.7 Ironwood Pharmaceuticals, Inc.
7.7.1 Overview
7.7.2 Ironwood Pharmaceuticals Inc. Products Portfolio
7.7.3 SCOT Analysis
7.8 Daiichi Sankyo Co. Ltd.
7.8.1 Overview
7.8.2 Daiichi Sankyo Product Portfolio
7.8.3 SCOT Analysis
7.9 Pfizer
7.9.1 Overview
7.9.2 Pfizer Product Portfolio
7.9.3 SCOT Analysis
7.10 Progenics Pharmaceuticals Inc
7.10.1 Overview
7.10.2 Progenics Pharmaceuticals Product Portfolio
7.10.3 SCOT Analysis

List of Figures
Fig. 1 Global OIC drugs market 2014-2022 (USD Mn)
Fig. 2 Global OIC Drugs Market by Drug Type, 2014 and 2020 (Value %)
Fig. 3 Global OIC Drugs Market, by Prescription Type, 2014 (%)
Fig. 4 Opioid Treatment Admissions and Sales, 1999-2010
Fig. 5 Opioid Prescription Statistics, 1993-2013 (USD Mn)
Fig. 6 Opioids Market: Growth Contributors
Fig. 7 Proportion of Population Aged 60 and Above, 2014
Fig. 8 Therapeutic Opioid Use in US (g/100,000 population)
Fig. 9 Common Side Effects of Movantik
Fig. 10 Considerations Taken for Opioid Usage
Fig. 11 Major Opioid Uses
Fig. 12 Global Methylnaltrexone Bromide OIC Drug Market 2014-2022 (USD Mn)
Fig. 13 Lubiprostone OIC Drug Market, 2014-2022 (USD Mn)
Fig. 14 Naloxegol OIC drug market 2014-2022 (USD Mn)
Fig. 15 Pipeline Product Profile: Elobixibat
Fig. 16 Global Prescribed OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 17 Global Prescribed Branded OIC drug market 2014-2022 (USD Mn)
Fig. 18 Global Prescribed Generic OIC Drugs Market, 2014 - 2022 (USD Mn)
Fig. 19 Global Over the Counter OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 20 North America OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 21 North America OIC Drugs Market, by Country, 2014-2022 (USD Mn)
Fig. 22 U.S. OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 23 U.S. OIC Drugs Market, by Prescription Type, 2014-2022 (USD Mn)
Fig. 24 Canada OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 25 Total Number of Prescriptions Dispensed for Opioids in Canada, 2010-2014
Fig. 26 Europe OIC Drugs Market, 2014-2014 (USD Mn)
Fig. 27 U.K. OIC Drugs Market, 2014-2022 (%)
Fig. 28 Germany OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 29 Rest of Europe OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 30 Asia Pacific OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 31 Asia Pacific OIC Drugs Market, by Country, 2014-2022 (USD Mn)
Fig. 32 China OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 33 Japan OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 34 APAC OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 35 RoW OIC Drugs Market, by Region, 2014-2022 (USD Mn)
Fig. 36 Middle East and Africa OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 37 Latin America OIC Drugs Market, 2014-2022 (USD Mn)
Fig. 38 Rest of RoW OIC Drugs Market, 2014-2022 (USD Mn)

List of Tables
Table 1 Global OIC drug market by geography 2014-2022 (USD Mn)
Table 2 Pharmacological approaches to treat opiate-induced constipation
Table 3 Laxatives Used for Opioid-induced Constipation
Table 4 Common Side-effects of Using Laxatives
Table 5 Patients Unfit for Intake of Opioids
Table 6 Global OIC Drug Market, by Drug Type, 2014-2022(USD Mn)
Table 7 Global Product profile (Methylnaltrexone Bromide)
Table 8 Global Methylnaltrexone Bromide OIC Drug Market, by Geography 2014-2022 (USD Mn)
Table 9 Product Profile (Lubiprostone)
Table 10 Global Lubiprostone OIC Drug Market, by Geography, 2014-2022 (USDMn)
Table 11 Product profile: Naloxegol
Table 12 Naloxegol OIC drug market by geography 2014-2022 (USDMn)
Table 13 Pipeline Product Profile (Naldemedine)
Table 14 Pipeline Product Profile: Alvimopan, Dolcanatide
Table 15 Global OIC Drugs Market, by Prescription Type, 2014 (%)
Table 16 Global Prescribed OIC Drugs Market, by Prescription Type, 2014-2022 (USD Mn)
Table 17 U.S. OIC Drugs Market, by Drug Type, 2014-2022 (USD Mn)
Table 18 U.S. Prescribed OIC Drugs Market, by Prescription Type, 2014-2022 (USD Mn)
Table 19 Europe OIC Drugs Market, by Country, 2014-2022 (USD Mn)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Astrazenenca
  • Shionogo & Co Ltd
  • Salix Pharmaceuticals Ltd
  • Synergy Pharmaceuticals Inc
  • Cubist Pharmaceuticals (Adolor Corporation) – A Subsidary Of Merck
  • Sucampo Pharmaceuticals
  • Ironwood Pharmaceuticals, Inc.
  • Daiichi Sankyo Co. Ltd.
  • Pfizer
  • Progenics Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll